Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, et al. Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer Res. 2024;84(11):1834-1855.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15:363.

Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, et al. Canonical AREs are tumor suppressive regulatory elements in the prostate. bioRxiv. 2024.

Yuan G, Lin X, Liu Y, Greenblatt MB, Xu R. Skeletal stem cells in bone development, homeostasis and disease. Protein Cell. 2024.

Keltner NM, Cushing MM, Haas T, Spinella PC. Analyzing and modeling massive transfusion strategies and the role of fibrinogen-How much is the patient actually receiving? Transfusion. 2024.

de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, et al. Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease. Am J Kidney Dis. 2024.

Jain D, Khandakar B, Ni P, Kenney B, Qin L, Deshpande V, et al. von Meyenburg complexes are more frequently associated with cholangiocarcinoma. J Clin Pathol. 2024.

Magro CM, Sanders S. Tumor necrosis factor ALPHA Inhibitor Associated Köhlmeier-Degos Disease as a Novel Iatrogenic Paradigm That Underscores Excessive Type I Interferon in Its Pathogenesis. Am J Dermatopathol. 2024;46(9):605-610.

Zhang BX, Brantley KD, Rosenberg SM, Kirkner GJ, Collins LC, Ruddy KJ, et al. Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Res Treat. 2024;207(3):587-597.

Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, et al. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024;116(1):115-126.